Finance

Lists
CAH:NYSE
Cardinal Health, Inc
$234.85
-0.06%
(-0.13) 1D
$232.81
-0.87% (-2.04)
After hours
Closed: Aug 19, 4:00:04 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CAH...
Open
$236.41
High
$238.15
Low
$232.34
Mkt. cap
54.62B
Avg. vol.
2.20M
Volume
0.00
Dividend
0.88%
Quarterly dividend
$0.52
Ex-dividend date
Jul 1, 2026
P/E ratio
32.47
52-wk high
$258.30
52-wk low
$145.87
EPS
$7.23
Beta
0.49
Shares outstanding
232.58M
No. of employees
61K
Open
$236.41
High
$238.15
Low
$232.34
Mkt. cap
54.62B
Avg. vol.
2.20M
Volume
0.00
Dividend
0.88%
Quarterly dividend
$0.52
Ex-dividend date
Jul 1, 2026
P/E ratio
32.47
52-wk high
$258.30
52-wk low
$145.87
EPS
$7.23
Beta
0.49
Shares outstanding
232.58M
No. of employees
61K
News stories
From web sources and news partners
Profile
Cardinal Health Technologies, LLC doing business as Cardinal Health, is an American multinational health care services company, and the 15th highest revenue generating company in the United States. Headquartered in Dublin, Ohio, the company specializes in the distribution of pharmaceuticals and medical products, serving more than 100,000 locations. The company also manufactures medical and surgical product, including gloves, surgical apparel, and fluid management products. In addition, it operates one of the largest networks of radiopharmacies in the U.S. Cardinal Health provides medical products to over 75 percent of hospitals in the United States. Wikipedia
About Cardinal Health, Inc
CEOJason Hollar
Employees61.3K
Founded1971
HeadquartersDublin, Ohio, United States
SectorHealth care provider
Websitecardinalhealth.com
Analyst ratings
Based on 15 analysts giving stock ratings to CAH in the past 3 months
Strong buy
Buy
13
Hold
2
Sell
0
12-month forecast
Based on 15 Wall Street analysts offering 12 month price targets for CAH in the last 3 months.
Highest
Current $234.85
$292.00 (+24.33%)
Average
$270.00 (+14.97%)
Lowest
$250.00 (+6.45%)
Analyst
Recommendation
Action
Price target
Projected
Date
Glen Santangelo
Barclays
Buy
Reiterated
$275.00
+17.1%
08/18/2026
Ryan Halsted
RBC Capital
Buy
Initiated
$276.00
+17.5%
08/19/2026
Lisa Gill
J.P. Morgan
Hold
Maintained
$260.00
+10.7%
08/17/2026
George Hill
Deutsche Bank
Hold
Maintained
$261.00
+11.1%
08/13/2026
Steven Valiquette
Mizuho Securities
Buy
Maintained
$250.00
+6.5%
08/13/2026
Charles Rhyee
TD Cowen
Buy
Reiterated
$280.00
+19.2%
08/13/2026
Elizabeth Anderson CFA
Evercore ISI
Buy
Maintained
$270.00
+15%
08/12/2026
Erin Wright
Morgan Stanley
Buy
Maintained
$255.00
+8.6%
08/12/2026
Stephen Baxter
Wells Fargo
Buy
Reiterated
$277.00
+17.9%
08/12/2026
Daniel Grosslight
Citi
Buy
Maintained
$280.00
+19.2%
08/12/2026
Unknown Analyst
Wells Fargo
Buy
Reiterated
$277.00
+17.9%
08/12/2026
Michael Cherny
Leerink Partners
Buy
Maintained
$292.00
+24.3%
08/11/2026
Ryan Daniels
William Blair
Buy
Reiterated
-
-
08/11/2026
Allen Lutz
Bank of America Securities
Buy
Maintained
$260.00
+10.7%
07/20/2026
Kevin Caliendo
UBS
Buy
Reiterated
$274.00
+16.7%
07/20/2026
Unknown Analyst
William O'Neil
Buy
Initiated
-
-
06/12/2026
Unknown Analyst
Argus Research
Buy
Maintained
$248.00
+5.6%
05/05/2026
Steven Silver
Argus Research
Buy
Maintained
$248.00
+5.6%
05/05/2026
Eric Coldwell
Robert W. Baird
Buy
Maintained
$248.00
+5.6%
05/01/2026
Max Smock
William Blair
Buy
Initiated
-
-
04/28/2026
Last report
Aug 11, 2026
Fiscal period
Q4 2026
EPS / Est. (USD)
$2.60 / $2.42
+7.41%beat
Revenue / Est. (USD)
63.67B / 65.11B
-2.20%miss
Fiscal Q4 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
64.01B
65.63B
60.94B
63.67B
Cost of goods sold
61.69B
63.23B
58.44B
61.11B
Cost of revenue
61.69B
63.23B
58.44B
61.11B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.46B
1.50B
1.54B
1.62B
Operating expense
1.55B
1.59B
1.64B
1.71B
Total operating expenses
63.24B
64.82B
60.08B
62.82B
Operating income
771.00M
809.00M
861.00M
847.00M
Other non operating income
10.00M
11.00M
-16.00M
30.00M
EBT including unusual items
598.00M
630.00M
392.00M
554.00M
EBT excluding unusual items
701.00M
732.00M
744.00M
794.00M
Income tax expense
144.00M
159.00M
12.00M
154.00M
Effective tax rate
24.08%
25.24%
3.06%
27.80%
Other operating expenses
-
-
-
-
Net income
450.00M
467.00M
399.00M
398.00M
Net profit margin
0.70%
0.71%
0.65%
0.62%
Earnings per share
2.55
2.63
3.17
2.60
Interest and investment income
-
-
-
-
Interest expense
-80.00M
-88.00M
-101.00M
-103.00M
Net interest expenses
-80.00M
-88.00M
-101.00M
-103.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
1.00B
1.04B
1.11B
1.09B
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps